Lymphoma Canada Accomplishments

Bi-Annual Report 2024

A MESSAGE FROM LYMPHOMA CANADA

In the second half of 2024, Lymphoma Canada focused its efforts on delivering essential educational and support services to patients across the country. Achieving our mission is a collective effort, and we are deeply grateful to the many healthcare professionals who have contributed. The guidance and support from our Scientific Advisory Board, Nursing Advisory Board, and Patient Family Advisory Committee have been pivotal in driving our progress. As we look back, we are filled with immense gratitude for the ongoing support that has fueled our accomplishments and furthered our mission.

OUR VISION

LYMPHOMA CANADA

Life Unlimited by Lymphoma

2024 ACCOMPLISHMENTS (JUL-DEC)

EDUCATION

- In 2024, we distributed nearly 6,000 resources free of charge, sharing them with patients, hospitals and cancer centers across Canada.
- In regards to our continuous effort to inform patients and caregivers about updates on disease trajectory and treatment, we hosted a series of webinars in the last few months including: Supportive Care and Palliative Care for Lymphoma Patients, Mantle Cell Lymphoma, Treatment for T-Cell Lymphomas (FR), Mindfulness and Stress Reduction for Lymphoma Patients, and Clinical Trials for Lymphoma and CLL Patients
- We hosted our National Conference over three days, October 16th-18th, with over 650 registrants attending, and expert speakers presenting on new and relevant lymphoma and CLL topics.
- We launched our new "Ask a Lymphoma/CLL Specialist" Q&A program, with close to 400 registrants, providing patients with the opportunity to ask their questions directly to a specialist.
- Lymphoma Canada released a series of new educational resources including a Coping with Fatigue Guide, End of Life Guide, and Side effects factsheets for CRS and ICANS.

SUPPORT

- Frequently we hear patients and caregivers say that they would benefit from speaking with someone who has been through a similar experience. Lymphoma Canada continues to connect patients and caregivers through the Lymphoma Canada Peer-to-Peer Mentorship Program to help meet the need for support.
- In collaboration with Wellspring, we continue to co-host virtual monthly support groups for lymphoma patients.
- We provide ongoing, one-on-one information and support to patients and caregivers directly through phone and email.

🔥 ADVOCACY

- Lymphoma Canada participated in all patient submission opportunities with respect to lymphoma and CLL therapies to the CDA (Canadian Drug Association) and the Quebec equivalent, INESSS.
- Lymphoma Canada launched a new awareness campaign in 2024 aimed at increasing understanding of rare lymphoma subtypes. The campaign seeks to educate the public and healthcare professionals about these less common forms of lymphoma, with the goal of improving early detection, diagnosis, and treatment options for patients.
- Lymphoma Canada partnered with the Lymphoma Coalition to gain deeper insights into the patient and caregiver experience through a global survey. With over 700 responses from Canadians, Lymphoma Canada will publish reports in early 2025 that summarize the overall patient and caregiver experience, along with insights specific to different lymphoma subtypes including CLL, DLBCL, etc.



RESEARCH

We received several excellent research award applications in 2024 and awarded the research grant to:

• Dr. Robert Vanner and Dr. Rob Laister for their research project on **Somatic Mutation as a Novel Determinant** of CAR-T Outcome in Lymphoma

ONGOING AND UPCOMING STRATEGIC PRIORITIES

EDUCATION

- New resources are to be released in 2025 including updated subtype factsheets and side effects guide, as well as a Patient and Caregiver Guide to CAR T-cell Therapy.
- 2025 educational webinars on topics including: 2024 ASH Update for Lymphoma & CLL Patients, Nutrition and Wellness for Lymphoma Patients, Navigating Watch and Wait, amongst other interesting topics.

SUPPORT

Our goal is to broaden the reach of our support programs, specifically our Lymphoma Links one on one peer mentorship program.

ADVOCACY

- Development of Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma National Treatment Guidelines.
- Continued participation in 100% of all new lymphoma therapy CDA/INESSS submissions.

Thank You

We extend our heartfelt thanks to the many donors and sponsors whose generosity has been vital in helping us continue our work in 2024 and beyond. Your support has empowered us to provide patients and caregivers with crucial resources, offer valuable knowledge about lymphoma, and assist them in navigating the ever-changing landscape of cancer care over the past year. The milestones reached in 2024 have been exceptional, and we look forward to even greater achievements as we move into 2025. Thank you for choosing Lymphoma Canada as a trusted partner in your lymphoma or CLL journey.

_YMPHOMA ^{Mississ} CANADA Toll fre

6860 Century Avenue, Suite 202 Mississauga, ON L5N 2W5

Toll free: 1-866-659-5556 General Inquiries: <u>info@lymphoma.ca</u> Website: <u>https://www.lymphoma.ca/</u> Charitable Registration Number 87346 1040 RR0001